Search Results for “EC” – Page 64 – media

BridGene inks collaboration and licensing agreement with Galapagos to discover small molecule drugs for oncology targets

BridGene Biosciences, Inc., a leader in the discovery of small molecule drugs for traditional “hard-to-drug” targets, announced a strategic collaboration and licensing agreement with Galapagos NV. Under the collaboration, BridGene will use its chemoproteomics platform, IMTAC, to discover novel small molecule drug candidates against the collaboration targets. The parties will collaborate to advance the molecules to clinical candidates, which Galapagos has the exclusive rights to develop and commercialize. The preclinical research collaboration will focus on oncology targets named by Galapagos. Galapagos will pay BridGene up to $27 million in upfront and preclinical research milestone payments and more than $700 million in clinical and commercial milestones, assuming success of the programs. BridGene is also eligible to receive tiered royalties on net sales of each product resulting from the collaboration. “BridGene’s proven expertise in discovering small molecule drugs for challenging targets positions them as an ideal partner in pioneering new avenues in ...
- Source: drugdu
- 100
- January 9, 2024
Owkin and Evotec partner to accelerate therapeutics in oncology and I&I

The companies will aim to select targets, discover and develop new therapeutics Owkin and Evotec have entered into an artificial intelligence (AI)-powered strategic partnership in oncology, immunology and inflammation (I&I). Both companies will collaborate to accurately select targets, discover and develop new therapeutics. As part of the agreement, the French-American techbio company, Owkin, will identify indication-relevant targets and subgroups using AI applied to multimodel patient data with its cutting-edge target discovery engine. Evotec will utilise its shared research and development (R&D) platform to accelerate and de-risk the validation of targets, the identification of drug candidates and the successful completion of pre-clinical development activities up to an investigational new drug application (IND). In addition, an Owkin-Evotec joint research strategy team will steer the collaboration to design fully tailored strategic programme plans from target selection to IND, as well as ensuring the delivery of the programmes. Evotec will receive R&D funding from ...
- Source: drugdu
- 85
- January 9, 2024
UK online pharmacies selling prescription drugs without proper checks

Some UK online pharmacies are selling high-risk prescription drugs based on online questionnaires, a BBC investigation has found. The news organisation was able to buy over 1,600 pills from 20 pharmacies without challenge, raising concerns over the level of regulation these companies face. The BBC found that unnamed prescription-only drugs including painkillers anti-anxiety medication and benzodiazepines (a depressant drug group including Valium) were available by providing false information and without the need for a video consultation or medical records. Online pharmacies in the UK are regulated by the General Pharmaceutical Council (GPhC) and are unable to prescribe drugs without approval from a qualified pharmacist. This should in theory make these sites safe, but it also allows them to operate without heavy oversight. The GPhC gives guidance, and is able to take regulatory action should breaches be deemed dangerous enough, but pharmacist and former chair of the Royal Pharmaceutical Society Thorrun ...
- Source: drugdu
- 78
- January 9, 2024
China Biological Wuhan Institute of Biological Products Receives Another International Registration Certificate for Influenza Vaccine

On January 3, 2024, the quadrivalent influenza virus lysate vaccine independently developed by Wuhan Institute of Biological Products of China Biologicals (WIBP) was granted a certificate of drug registration by the Ministry of Health and Prevention (MOHAP) of the United Arab Emirates (UAE). This is another international registration certificate obtained after the Kenyan registration certificate in 2023, marking the steady progress of the internationalization strategy of Wuhan Bioproducts Research Institute and the gradual opening of a new channel for exporting vaccine products to the Middle East. Influenza is an acute respiratory infectious disease caused by influenza virus. According to WHO’s estimation, about 600 million people are infected with influenza virus globally every year, and as many as 250,000 to 500,000 cases of death. Influenza vaccination is the most cost-effective preventive measure. Influenza vaccine of Wuhan Institute of Biological Products is prepared by a patented process without antibiotics and preservatives. It ...
- Source: drugdu
- 75
- January 9, 2024
Optimizing patient care with the best risk scores

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Risk prediction models are an important part of assessing operative mortality and postoperative complication rates in current cardiac surgery practice. Furthermore, they guide clinical decision-making and perioperative patient management. In recent years, a variety of clinical prediction models have been developed in China and other countries to assess the risk of mortality and complications after cardiac surgery. Currently, the most widely used and mature models are the new version of the European Cardiac Surgery Evaluation System (EuroSCORE II), the American Society of Thoracic Surgeons Cardiac Surgery Risk Model (STS score), and the Chinese Coronary Artery Bypass Graft Surgery Risk Evaluation System (SinoSCORE). This article reviews the application of these three risk prediction models, to identify the optimal model for guiding clinical practice. Source: https://www.news-medical.net/news/20240105/Precision-surgery-powered-by-prediction-Optimizing-patient-care-with-the-best-risk-scores.aspx
- Source: drugdu
- 88
- January 8, 2024
Hengrui’s Innovative Drugs Piratinib and Dalsili Breast Cancer Indications Both Recommended by 2024 CBCS Guidelines

Recently, the Chinese Breast Cancer Society Breast Cancer Diagnosis and Treatment Guidelines (2024 Edition) (hereinafter referred to as the CBCS Guidelines) has been updated and released. As one of the most important and authoritative Chinese diagnosis and treatment norms in the field of breast cancer, the CBCS Guidelines follow the international pace and cutting-edge progress, and comprehensively summarize and elaborate on breast cancer screening, examination, diagnosis and treatment, and reporting. In this guideline recommendation, two new indications for Hengrui Pharmaceuticals’ innovative drugs have been added, which are the first-line treatment regimen of piretinib combination for HER2-positive metastatic breast cancer, and the first- and second-line treatment regimen of dalsirib for HR-positive HER2-negative metastatic breast cancer (MBC). Thus, both innovative drugs have been recommended by the 2024 CBCS guidelines for the marketed breast cancer indications. Breast cancer has become the number one malignant tumor worldwide and is one of the most common ...
- Source: drugdu
- 163
- January 7, 2024
Treatment of Orthopedic Postoperative Pain, Hengrui Pharmaceuticals’ New Drug Application for Tegretol Fumarate Injection Accepted

Postoperative pain is acute pain that occurs immediately after surgery. Inadequate management of postoperative pain may lead to a variety of psychological and physiological negative effects, such as persistent pain and the possibility of turning into a chronic state. Opioids are the most commonly used drugs for the treatment of moderate to severe acute and chronic pain. Classical μ-opioid receptor (MOR) agonists, including morphine and fentanyl, are among the more potent analgesic classes of opioids and can activate both the G protein-coupled pathway and the β-arrestin2 signaling pathway.Activation of the G protein-coupled pathway is conducive to a potent central analgesic effect, whereas activation of the β-arrestin2 signaling pathway causes gastrointestinal side effects, such as gastrointestinal dysphoria. Side effects. Currently, there are no biased MOR agonists with good analgesic effects and low incidence of adverse effects on the market in China, and there is an unmet clinical need. In December 2023, ...
- Source: drugdu
- 88
- January 7, 2024
Rapid Bedside Test to Protect Newborns from Life-Threatening Illnesses

Group B Streptococcus (GBS), a bacterial strain, is the leading cause of severe infections in newborns in the UK. Around one in four pregnant women in the UK are carriers of GBS, often unknowingly, and during childbirth, there’s a 50% chance of transmitting the bacteria to the baby. While most exposed infants remain healthy, approximately one in 1,750 will develop early-onset GBS infections, including sepsis, pneumonia, or meningitis, which can have severe consequences. The UK currently employs a ‘risk factor-based screening’ approach, providing antibiotics during labor to women identified with GBS during pregnancy or those with a previous baby affected by GBS. However, this strategy fails to detect many GBS carriers, with about 65% of early-onset GBS infections in newborns occurring in babies whose mothers had no identified risk factors. Now, a research project is examining the potential of a rapid bedside test for safeguarding newborns from life-threatening illnesses transmitted ...
- Source: drugdu
- 161
- January 6, 2024
Nalu Medical raises $65M for neurostim tech

BY SEAN WHOOLEY Nalu Medical announced today that it closed a $65 million equity financing to support its minimally invasive neurostimulation product. Carlsbad, California–based Nalu had its round led by new investor Novo Holdings. All existing significant investors — including Gilde Healthcare, MVM Partners, Endeavor Vision, Decheng Capital, Longitude Capital, Advent Life Sciences, Pura Vida and Aperture Venture Partners — participated, too. Nalu plans to use the proceeds to accelerate commercial growth and expand clinical and health-economic evidence. It also wants to use the funds to continue product development and scale operations. The company’s FDA-cleared spinal cord stimulation and peripheral nerve stimulation technology treats patients with chronic neuropathic pain. It delivers gentle electrical pulses to the nervous system to modulate pain signals before they reach the brain. Nalu system includes a fully featured, battery-free, miniaturized implantable pulse generator (IPG). An externally worn therapy disc wirelessly powers the IPG and ...
- Source: drugdu
- 173
- January 6, 2024
FDA Grants Fast Track, Breakthrough Designations to CG Oncology Inc’s Cretostimogene Grenadenorepvec

Pharmaceutical Executive Editorial Staff Cretostimogene grenadenorepvec (CG0070) is currently being evaluated for the treatment of patients with high-risk Bacillus Calmette-Guérin–unresponsive non–muscle invasive bladder cancer with carcinoma in situ with or without Ta or T1 tumors. The FDA granted Fast Track and Breakthrough Therapy designations to CG Oncology Inc’s cretostimogene grenadenorepvec (CG0070) for the treatment of patients with high-risk Bacillus Calmette-Guérin (BCG)–unresponsive non–muscle invasive bladder cancer (NMIBC) with carcinoma in situ with or without Ta or T1 tumors.1 The novel, intravesically delivered oncolytic immunotherapy is currently being evaluated in the Phase III BOND-003 and the Phase II CORE-001 clinical trial in combination with pembrolizumab (Keytruda) in the same indication. An investigator-sponsored clinical trial is evaluating cretostimogene grenadenorepvec in combination with nivolumab (Opdivo) for the treatment of muscle invasive bladder cancer. The regulatory action was based on data from an ongoing clinical trial program, including the Phase III BOND-003 trial (NCT04452591), which ...
- Source: drugdu
- 145
- January 6, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.